New Delhi, Feb 26 (PTI) Sanofi Pasteur today said its affiliate Shantha Biotechnics has received approval from the World Health Organization for storage of its oral cholera vaccine Shanchol at high temperatures, thus increasing its availability. Also Read - Serum Institute to Produce up to Additional 100 Million COVID-19 Vaccine Doses For India in 2021
After the approval by the WHO, Shanchol may be kept for a single period of time at temperature of up to 40 C for up to 14 days immediately prior to administration. Also Read - Monsoon Session Day 2: Lok Sabha Passes Essential Commodities Bill to Raise Farmer Income, Boost Agri Sector | Highlights
The approval is of great significance to regions where the vaccine is used, including India, as it eliminates the challenges of maintaining the vaccine cold chain during transport, Sanofi Pasteur said in a statement. Also Read - 'Jammu And Kashmir to Reopen For Tourism Soon', Says J&K Administration
Shantha Biotechnics’ Executive Director and COO Mahesh Bhalgat said : “This is a significant milestone in our efforts towards effective cholera prevention and control.” WHO’s approval will help make Shanchol available to populations living in remote, hard-to-reach areas of India and other parts of the world, especially ones with erratic electricity supply, he added.
The WHO approval for use of Shanchol in controlled temperature chain was granted after a review of its stability data, the statement said.
“This important development will make it easier to deliver vaccines to the remote areas where it is desperately needed, saving lives and contributing to the global effort to finally consign this disease to the history books,” said Anuradha Gupta, Deputy CEO of Gavi, the Vaccine Alliance.
Cholera is caused by a bacterium, vibrio cholerae, which produces a toxin that affects the intestines.
“The storage label change takes us a few steps closer to our vision of a world where no lives are lost to preventable infectious diseases, as it has the potential to significantly change cholera control efforts for the better, not only in India but also in other parts of the world where the vaccine is needed the most,” Sanofi India MD N Rajaram said. PTI AKT AKT ABM ABM
This is published unedited from the PTI feed.